{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056958","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.898814+00:00","generated_at":"2026-06-02T05:49:32.742288+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Clearside reports Q1 net loss $11.8M, $0.17/sh; cash $35.4M; ODYSSEY topline due Q3 2024","bullets":["Net loss $11.8M ($0.17/sh) vs $9.3M ($0.15) Q1 2023; revenue $230K up from $4K.","Cash $35.4M expected to fund operations into Q3 2025.","Phase 2b ODYSSEY trial of CLS-AX in wet AMD topline data expected Q3 2024.","Appointed Victor Chong as CMO (March 2024) and Tony Gibney to Board (April 2024).","Completed $15M registered direct offering in Feb 2024; new CPT code for XIPERE effective Jan 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056958","json":"https://secwatch.observer/filing/0000950170-24-056958.json","markdown":"https://secwatch.observer/filing/0000950170-24-056958.md","text":"https://secwatch.observer/filing/0000950170-24-056958.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017024056958/0000950170-24-056958-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017024056958/clsd-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:49:32.742288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27fde4a41eb6b8871d2041b1c418e6ed9290699a","claim":"Clearside Biomedical, Inc. reported first quarter ended March 31, 2024 results: revenue $230,000, net income $11.8 million, EPS $0.17 per share of common stock.","evidence_excerpt":"by delivering drug directly to the back of the eye via the SCS Microinjector. First Quarter 2024 Financial Results • License and other revenue for the first quarter of 2024 was $230,000, compared to $4,000 for the first quarter of 2023. • Research and development expenses for the first quarter of 2024 were $5.6 million, compared to $4.5 million for the first","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017024056958/0000950170-24-056958-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$230,000"},{"label":"Net income","value":"$11.8 million"},{"label":"EPS","value":"$0.17 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}